BIOMAT Database Logo BIOMAT Database Logo

Targeting the alpha-folate receptor with cyclopenta[g]quinazoline-based inhibitors of thymidylate synthase. 2006

Elisa A Henderson, and Vassilios Bavetsias, and Davinder S Theti, and Stuart C Wilson, and Rainer Clauss, and Ann L Jackman
Department of Chemistry, Cancer Research UK Centre for Cancer Therapeutics at The Institute of Cancer Research, Cancer Research Laboratories, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK.

The alpha-FR has been reported to be overexpressed in many carcinomas, in particular those of the ovary and uterus. The high expression of alpha-FR in some tumours compared with normal tissues has been exploited over the last decade for folate-mediated targeting of macromolecules, anticancer drugs, imaging agents and nucleic acids to cancer cells. CB300638, a cyclopenta[g]quinazoline-based inhibitor of thymidylate synthase (TS), has been reported to have high affinity for the receptor and selectivity for alpha-FR overexpressing tumour cell lines. In this study, the structural features of the molecule, in particular modifications at the 2-position, have been investigated with respect to TS inhibition, affinity for the alpha-FR and reduced folate carrier (RFC) and activity in A431-FBP cells (transfected with human alpha-FR) compared with neo-transfected A431 cells. Compounds 1a,b, 2a,b and 3a,b were synthesised utilising multistep sequences. It was found that the 2-substituent does not affect the affinity for the alpha-FR; however, it greatly affects selectivity for A431-FBP cells, and suggests that there are factors other than TS inhibition and alpha-FR affinity that are important for the activity of these compounds. Compound 2b (2-CH2OH derivative) displayed the highest selectivity for the A431-FBP cells compared with A431 cells.

UI MeSH Term Description Entries
D011799 Quinazolines A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring. Quinazoline
D011956 Receptors, Cell Surface Cell surface proteins that bind signalling molecules external to the cell with high affinity and convert this extracellular event into one or more intracellular signals that alter the behavior of the target cell (From Alberts, Molecular Biology of the Cell, 2nd ed, pp693-5). Cell surface receptors, unlike enzymes, do not chemically alter their ligands. Cell Surface Receptor,Cell Surface Receptors,Hormone Receptors, Cell Surface,Receptors, Endogenous Substances,Cell Surface Hormone Receptors,Endogenous Substances Receptors,Receptor, Cell Surface,Surface Receptor, Cell
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002352 Carrier Proteins Proteins that bind or transport specific substances in the blood, within the cell, or across cell membranes. Binding Proteins,Carrier Protein,Transport Protein,Transport Proteins,Binding Protein,Protein, Carrier,Proteins, Carrier
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D003517 Cyclopentanes A group of alicyclic hydrocarbons with the general formula R-C5H9. Cyclopentadiene,Cyclopentadienes,Cyclopentene,Cyclopentenes,Cyclopentane
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013940 Thymidylate Synthase An enzyme of the transferase class that catalyzes the reaction 5,10-methylenetetrahydrofolate and dUMP to dihydrofolate and dTMP in the synthesis of thymidine triphosphate. (From Dorland, 27th ed) EC 2.1.1.45. Thymidylate Synthetase,Synthase, Thymidylate,Synthetase, Thymidylate

Related Publications

Elisa A Henderson, and Vassilios Bavetsias, and Davinder S Theti, and Stuart C Wilson, and Rainer Clauss, and Ann L Jackman
Selective delivery of CB300638, a cyclopenta[g]quinazoline-based thymidylate synthase inhibitor into human tumor cell lines overexpressing the alpha-isoform of the folate receptor.
July 2003, Cancer research,
Elisa A Henderson, and Vassilios Bavetsias, and Davinder S Theti, and Stuart C Wilson, and Rainer Clauss, and Ann L Jackman
Design and synthesis of Cyclopenta[g]quinazoline-based antifolates as inhibitors of thymidylate synthase and potential antitumor agents(,).
May 2000, Journal of medicinal chemistry,
Elisa A Henderson, and Vassilios Bavetsias, and Davinder S Theti, and Stuart C Wilson, and Rainer Clauss, and Ann L Jackman
Cyclopenta[g]quinazoline-based antifolates: the effect of the chirality at the 6-position on the inhibition of thymidylate synthase (TS).
December 2001, Bioorganic & medicinal chemistry letters,
Elisa A Henderson, and Vassilios Bavetsias, and Davinder S Theti, and Stuart C Wilson, and Rainer Clauss, and Ann L Jackman
Structure-based design of lipophilic quinazoline inhibitors of thymidylate synthase.
February 1996, Journal of medicinal chemistry,
Elisa A Henderson, and Vassilios Bavetsias, and Davinder S Theti, and Stuart C Wilson, and Rainer Clauss, and Ann L Jackman
Folate-based thymidylate synthase inhibitors in cancer chemotherapy.
January 1997, Anti-cancer drugs,
Elisa A Henderson, and Vassilios Bavetsias, and Davinder S Theti, and Stuart C Wilson, and Rainer Clauss, and Ann L Jackman
Folate-based thymidylate synthase inhibitors as anticancer drugs.
November 1995, Annals of oncology : official journal of the European Society for Medical Oncology,
Elisa A Henderson, and Vassilios Bavetsias, and Davinder S Theti, and Stuart C Wilson, and Rainer Clauss, and Ann L Jackman
Quinazoline-based thymidylate synthase inhibitors: relationship between structural modifications and polyglutamation.
October 1995, Anti-cancer drug design,
Elisa A Henderson, and Vassilios Bavetsias, and Davinder S Theti, and Stuart C Wilson, and Rainer Clauss, and Ann L Jackman
Folate analogues as inhibitors of thymidylate synthase.
April 1987, Journal of medicinal chemistry,
Elisa A Henderson, and Vassilios Bavetsias, and Davinder S Theti, and Stuart C Wilson, and Rainer Clauss, and Ann L Jackman
Quinazoline antifolate thymidylate synthase inhibitors: heterocyclic benzoyl ring modifications.
May 1991, Journal of medicinal chemistry,
Elisa A Henderson, and Vassilios Bavetsias, and Davinder S Theti, and Stuart C Wilson, and Rainer Clauss, and Ann L Jackman
Imaging pharmacodynamics of the alpha-folate receptor-targeted thymidylate synthase inhibitor BGC 945.
May 2008, Cancer research,
Copied contents to your clipboard!